{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:31:18Z","timestamp":1790242278066,"version":"4.1.0"},"reference-count":54,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T00:00:00Z","timestamp":1520726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p> Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation of clinical trials, this review aims to highlight advances in the field from its early days to the current state of affairs as it pertains to the application of adenoviral oncolytic therapy to gastrointestinal cancers.<\/jats:p>","DOI":"10.3390\/biomedicines6010033","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T13:13:48Z","timestamp":1520860428000},"page":"33","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Oncolytic Adenoviruses in Gastrointestinal Cancers"],"prefix":"10.3390","volume":"6","author":[{"given":"Raquel","family":"Yokoda","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolni","family":"Nagalo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Borad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85205, USA"},{"name":"Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Center for Individualized Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA"},{"name":"Mayo Clinic Cancer Center, 5881 E Mayo Blvd, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/jso.24578","article-title":"Colorectal cancer-global burden, trends, and geographical variations","volume":"115","author":"Douaiher","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_2","unstructured":"Howlader, N.N.A., Krapcho, M., Miller, D., Bishop, K., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2017). SEER Cancer Statistics Review 1975\u20132014."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/biomedicines2010036","article-title":"Oncolytic Adenoviruses in Cancer Treatment","volume":"2","author":"Alemany","year":"2014","journal-title":"Biomedicines"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/JCM.00156-11","article-title":"Computational analysis of two species C human adenoviruses provides evidence of a novel virus","volume":"49","author":"Walsh","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.wjorl.2016.05.009","article-title":"The current status of oncolytic viral therapy for head and neck cancer","volume":"2","author":"Old","year":"2016","journal-title":"World J. Otorhinolaryngol. Head Neck Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000236457","article-title":"Antipeptide antibodies to adenovirus E1b protein indicate enhanced risk of celiac disease and dermatitis herpetiformis","volume":"101","author":"Lahdeaho","year":"1993","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/infdis\/jix294","article-title":"Etiology of Severe Acute Watery Diarrhea in Children in the Global Rotavirus Surveillance Network Using Quantitative Polymerase Chain Reaction","volume":"216","author":"Operario","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Westerberg, S., Hagbom, M., Rajan, A., Loitto, V., Persson, B.D., Allard, A., Nordgren, J., Sharma, S., Magnusson, K.E., and Arnberg, N. (2018). Interaction of human enterochromaffin cells with human enteric adenovirus 41 leads to serotonin release and subsequent activation of enteric glia cells. J. Virol.","DOI":"10.1128\/JVI.00026-18"},{"key":"ref_10","first-page":"3","article-title":"Adenovirus-mediated cancer gene therapy and virotherapy","volume":"25","author":"Fukazawa","year":"2010","journal-title":"Int. J. Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00535-004-1490-y","article-title":"Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer","volume":"40","author":"Ono","year":"2005","journal-title":"J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/01.sla.0000141197.57930.7a","article-title":"Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma","volume":"240","author":"Pin","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13564","DOI":"10.18632\/oncotarget.3769","article-title":"A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-13-0742","article-title":"A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S\/G2\/M phases","volume":"19","author":"Yano","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.18632\/oncotarget.1430","article-title":"Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_16","first-page":"10403","article-title":"Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma","volume":"8","author":"Qian","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_17","first-page":"1754","article-title":"[An antitumor effect of oncolytic adenovirus capable of selectively replicating in CEA-expressing cancer cells and its enhancement by 5-FU]","volume":"33","author":"Araki","year":"2006","journal-title":"Gan Kagaku Ryoho"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhou, X., Xie, G., Wang, S., Wang, Y., Zhang, K., Zheng, S., Chu, L., Xiao, L., Yu, Y., and Zhang, Y. (2012). Potent and specific antitumor effect for colorectal cancer by CEA and Rb double regulated oncolytic adenovirus harboring ST13 gene. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047566"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Koski, A., Karli, E., Kipar, A., Escutenaire, S., Kanerva, A., and Hemminki, A. (2013). Mutation of the fiber shaft heparan sulphate binding site of a 5\/3 chimeric adenovirus reduces liver tropism. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060032"},{"key":"ref_20","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"Cancer Stat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/hum.2006.126","article-title":"Modification of the Rb-binding domain of replication-competent adenoviral vector enhances cytotoxicity against human esophageal cancers via NF-\u03baB activity","volume":"18","author":"Yamada","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1158\/1078-0432.CCR-07-1528","article-title":"Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/cgt.2010.37","article-title":"Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma","volume":"17","author":"Ma","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_24","first-page":"151","article-title":"A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer","volume":"65","author":"Fujiwara","year":"2011","journal-title":"Acta Med. Okayama"},{"key":"ref_25","first-page":"822","article-title":"[Effect of CEA gene regulation on the anti-tumor activity of oncolytic adenovirus H101 to esophageal carcinoma]","volume":"33","author":"Zheng","year":"2011","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/v6020856","article-title":"Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo","volume":"6","author":"He","year":"2014","journal-title":"Viruses"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: An endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"Boehm","year":"1997","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jiang, K., Al-Diffhala, S., and Centeno, B.A. (2018). Primary Liver Cancers-Part 1: Histopathology, Differential Diagnoses, and Risk Stratification. Cancer Control, 25.","DOI":"10.1177\/1073274817744625"},{"key":"ref_29","first-page":"6428","article-title":"A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin","volume":"61","author":"Li","year":"2001","journal-title":"Cancer Res"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ijc.20581","article-title":"Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma","volume":"113","author":"Li","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3748\/wjg.v13.i5.683","article-title":"p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro","volume":"13","author":"Zhao","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00432-011-1138-2","article-title":"Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth","volume":"138","author":"He","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/j.1745-7254.2007.00672.x","article-title":"Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus","volume":"28","author":"Pan","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1349-7006.2008.01069.x","article-title":"Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma","volume":"100","author":"Hsieh","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jin, H., Lv, S., Yang, J., Wang, X., Hu, H., Su, C., Zhou, C., Li, J., Huang, Y., and Li, L. (2011). Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021307"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/1535-7163.MCT-16-0096","article-title":"An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma","volume":"15","author":"Li","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1089\/hum.2010.219","article-title":"Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma","volume":"22","author":"Wei","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/gt.2012.4","article-title":"Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma","volume":"20","author":"Liu","year":"2013","journal-title":"Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3892\/or.2012.2217","article-title":"The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES\/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma","volume":"29","author":"Li","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_41","first-page":"403","article-title":"Targeting gene-virus-mediated manganese superoxide dismutase effectively suppresses tumor growth in hepatocellular carcinoma in vitro and in vivo","volume":"29","author":"Huang","year":"2014","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00432-014-1835-8","article-title":"Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin","volume":"141","author":"Ma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00006676-200404000-00022","article-title":"Oncolytic virotherapy as a novel strategy for pancreatic cancer","volume":"28","author":"Sunamura","year":"2004","journal-title":"Pancreas"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/sj.mt.6300212","article-title":"Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.18632\/oncotarget.795","article-title":"Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts","volume":"4","author":"Jose","year":"2013","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2014.07.008","article-title":"A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus","volume":"192","author":"Jose","year":"2014","journal-title":"J. Control Release"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jconrel.2014.07.053","article-title":"A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues","volume":"192","author":"Yamamoto","year":"2014","journal-title":"J. Control Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/sj.gt.3302271","article-title":"Enhanced efficacy of Escherichia coli nitroreductase\/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector","volume":"11","author":"Chen","year":"2004","journal-title":"Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/0008-5472.CAN-07-0297","article-title":"Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2","volume":"67","author":"Schepelmann","year":"2007","journal-title":"Cancer Res"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/sj.onc.1208460","article-title":"Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (\u2018Telomelysin-RGD\u2019)","volume":"24","author":"Taki","year":"2005","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/0008-5472.CAN-05-1834","article-title":"Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy","volume":"66","author":"Zhang","year":"2006","journal-title":"Cancer Res"},{"key":"ref_52","first-page":"2966","article-title":"A dual-regulated oncolytic adenovirus carrying TAp63 gene exerts potent antitumor effect on colorectal cancer cells","volume":"9","author":"Luo","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"76044","DOI":"10.18632\/oncotarget.18340","article-title":"CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer","volume":"8","author":"Miura","year":"2017","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OV.S145262","article-title":"Oncolytic virus delivery: From nano-pharmacodynamics to enhanced oncolytic effect","volume":"6","author":"Yokoda","year":"2017","journal-title":"Oncolytic Virother."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/6\/1\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:56:38Z","timestamp":1760194598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/6\/1\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["biomedicines6010033"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines6010033","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,11]]}}}